JP Morgan Chase’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $45.4M | Buy |
1,324,668
+169,958
| +15% | +$7.59M | ﹤0.01% | 1454 |
|
|
2025
Q4 | $53.8M | Sell |
1,154,710
-104,012
| -8% | -$4.63M | ﹤0.01% | 1323 |
|
|
2025
Q3 | $52.4M | Buy |
1,258,722
+926,765
| +279% | +$29.6M | ﹤0.01% | 1382 |
|
|
2025
Q2 | $9.55M | Buy |
331,957
+66,462
| +25% | +$2.05M | ﹤0.01% | 2601 |
|
|
2025
Q1 | $8.9M | Sell |
265,495
-4,048
| -2% | -$151K | ﹤0.01% | 2645 |
|
|
2024
Q4 | $13.8M | Sell |
269,543
-16,413
| -6% | -$918K | ﹤0.01% | 2395 |
|
|
2024
Q3 | $14.6M | Buy |
285,956
+894
| +0.3% | +$46.1K | ﹤0.01% | 2276 |
|
|
2024
Q2 | $12.8M | Sell |
285,062
-90,924
| -24% | -$4.2M | ﹤0.01% | 2237 |
|
|
2024
Q1 | $17.6M | Buy |
375,986
+282,882
| +304% | +$11.1M | ﹤0.01% | 1994 |
|
|
2023
Q4 | $3.31M | Buy |
93,104
+38,674
| +71% | +$1.19M | ﹤0.01% | 3440 |
|
|
2023
Q3 | $1.62M | Buy |
54,430
+10,756
| +25% | +$222K | ﹤0.01% | 3711 |
|
|
2023
Q2 | $787K | Buy |
43,674
+3,161
| +8% | +$63K | ﹤0.01% | 4228 |
|
|
2023
Q1 | $651K | Buy |
40,513
+5,819
| +17% | +$108K | ﹤0.01% | 4322 |
|
|
2022
Q4 | $636K | Buy |
34,694
+2,004
| +6% | +$35.3K | ﹤0.01% | 4362 |
|
|
2022
Q3 | $642K | Buy |
32,690
+1,801
| +6% | +$36.7K | ﹤0.01% | 4297 |
|
|
2022
Q2 | $576K | Sell |
30,889
-50,847
| -62% | -$1.01M | ﹤0.01% | 4465 |
|
|
2022
Q1 | $1.79M | Buy |
81,736
+33,463
| +69% | +$677K | ﹤0.01% | 3840 |
|
|
2021
Q4 | $1.37M | Buy |
48,273
+25,213
| +109% | +$622K | ﹤0.01% | 4152 |
|
|
2021
Q3 | $486K | Buy |
23,060
+2,919
| +14% | +$61.1K | ﹤0.01% | 4747 |
|
|
2021
Q2 | $379K | Sell |
20,141
-46,963
| -70% | -$825K | ﹤0.01% | 4869 |
|
|
2021
Q1 | $1.03M | Sell |
67,104
-11,904
| -15% | -$185K | ﹤0.01% | 4206 |
|
|
2020
Q4 | $1.11M | Buy |
79,008
+68,921
| +683% | +$960K | ﹤0.01% | 3889 |
|
|
2020
Q3 | $152K | Buy |
10,087
+952
| +10% | +$14.6K | ﹤0.01% | 4498 |
|
|
2020
Q2 | $160K | Buy |
9,135
+5,482
| +150% | +$93.5K | ﹤0.01% | 4366 |
|
|
2020
Q1 | $53K | Sell |
3,653
-106
| -3% | -$2.17K | ﹤0.01% | 4705 |
|
|
2019
Q4 | $95K | Buy |
3,759
+22
| +0.6% | +$419 | ﹤0.01% | 4920 |
|
|
2019
Q3 | $56K | Buy |
3,737
+704
| +23% | +$13.7K | ﹤0.01% | 5131 |
|
|
2019
Q2 | $75K | Buy |
3,033
+946
| +45% | +$23.4K | ﹤0.01% | 5022 |
|
|
2019
Q1 | $48K | Buy |
2,087
+307
| +17% | +$7.54K | ﹤0.01% | 5149 |
|
|
2018
Q4 | $53K | Buy |
1,780
+167
| +10% | +$4.7K | ﹤0.01% | 5054 |
|
|
2018
Q3 | $46K | Buy |
+1,613
| New | +$47.9K | ﹤0.01% | 5220 |
|
Other funds holding CRNX
FCM
DCM
VCM
VPM
EC